Single-Needle Distal Return for Long-Term Arteriovenous Fistula Care

Recruiting N/A Interventional Study
Hemodialysis Access Arteriovenous Fistula Arteriovenous Fistula Cannulation Vascular Access Vascular Access Complication
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 100
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
100 (estimated)
Sponsor
Suzhou Municipal Hospital of Anhui Province · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Background: For millions of people worldwide with kidney failure, a well-functioning vascular access, like an arteriovenous fistula (AVF), is essential for life-sustaining hemodialysis. However, the standard method requires puncturing the same AVF with two needles three times a week, which over time can damage the vessel, leading to scarring, narrowing, and frequent failures. These complications …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adult patients (age ≥ 18 years). Diagnosis of end-stage kidney disease (ESKD) requiring maintenance hemodialysis (three times per week). Reliable use of a native arteriovenous fistula (AVF) as the primary vascular access for at least the past 3 months. Willing and able to p…
Contacts

Shan Wu, Doctor of Philosophy

86-0557-3032255

2671437948@qq.com

CONTACT